Welcome to the 2nd Raw Materials for Cell & Gene Therapy Summit
Securing High Grade Raw Materials for a Smoother Supply Chain
Unlock the future of cell and gene therapy manufacturing at the 2nd Raw Materials for Cell & Gene Therapy Summit. This is your exclusive opportunity to hear directly from regulatory and standards leaders such as Andrew Sarafanov (FDA) and Rebecca Potts (USP), as they share the latest thinking on BLA review expectations, raw material characterization, and the evolving global standards landscape.
With the cell and gene therapy industry facing increasing complexity and supply chain uncertainty, top innovators from Vertex, Genentech, and Bristol Myers Squibb will reveal how they're reengineering supplier strategies, through dual sourcing, co-development, and rigorous vendor qualification.
Explore real-world solutions to qualification challenges and variability risks with insights from Ultragenyx, Abeona Therapeutics, and Metagenomi. Through hands-on workshops, strategic roundtables, and high-impact networking, you’ll walk away with the connections and frameworks needed to strengthen your quality programs and stay ahead of regulatory expectations. The time to align, adapt, and advance is now.
World-Class Speaker Faculty Includes:
Companies on the Program:
Hear it from Your Peers:
Rocket Pharma
"This summit presented challenges and experiences shared by all industry leaders.”
- Previous Attendee, Raw Materials for Cell & Gene Therapy Summit
Stemcell Technologies
“This event is truly the first of its kind, bringing together therapeutic developers and raw material suppliers to harmonize about what the field needs to ensure safe, effective, and streamlined development of CGT products.”
- Previous Attendee, Raw Materials for Cell & Gene Therapy Summit
Abeona Therapeutics
“The meeting was very informative about where raw materials programs stand now and the expectation for the future.”
- Previous Speaker, Raw Materials for Cell & Gene Therapy Summit
Our Partners:
